The Director and CEO of USask’s Vaccine and Infectious Disease Organization, considers the results to date for the clinical trials of its COVID-19 vaccine to be very encouraging.

Dr. Volkder Gerdts says the interim results of the trial in Halifax show immune responses very comparable to other already approved vaccines.

VIDO also tested against the Delta variant, and it still has proven to be very effective.

The clinical trial continues in Halifax and now in Saskatchewan, with well over 500 people volunteering in this province.

Dr. Gerdts added that VIDO is also working with some countries in Africa, so a clinical trial is happening there as well.

Gerdts explained that the VIDO vaccine is easy to handle, transport and store, so it may be handy and cost-effective to use where transport is an issue, like low and middle income countries, including remote locations in Africa.

(CJWW)